Current strategies in the management of hormone refractory prostate cancer
- 1 June 2003
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 29 (3), 171-187
- https://doi.org/10.1016/s0305-7372(02)00090-7
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signalingOncogene, 2001
- SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCERJournal of Urology, 2001
- Molecular cytogenetics of prostate cancerMicroscopy Research and Technique, 2000
- A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinomaCancer, 2000
- Genetic Alterations in Hormone-Refractory Recurrent Prostate CarcinomasThe American Journal of Pathology, 1998
- Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate CancerThe New England Journal of Medicine, 1995
- Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate CancerJNCI Journal of the National Cancer Institute, 1994
- Trimetrexate in advanced hormone-refractory prostate cancerInvestigational New Drugs, 1994
- Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group StudyEuropean Journal of Cancer, 1992